Stock data
Grace Therapeutics, Inc. (GRCE)
Grace Therapeutics, Inc. (GRCE) reported net income of -US$7.79M for fiscal 2026. The figures below come from the company's SEC filings.
Annual results
Data as of 2026-03-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2026 | — | — | -US$11.08M | -US$7.79M | — |
| 2025 | — | — | -US$16.68M | -US$9.57M | — |
| 2024 | — | — | -US$12.85M | -US$12.85M | — |
| 2023 | — | — | -US$52.16M | -US$42.43M | — |
| 2022 | US$100.00M | — | -US$15.59M | -US$9.82M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$15.79M | — |
| 2026-03-31 | — | -US$1.18M | — |
| 2025-12-31 | — | -US$2.31M | — |
| 2025-09-30 | — | -US$0.94M | — |
| 2025-06-30 | — | -US$3.36M | — |
| 2025-03-31 | — | US$0.64M | — |
| 2024-12-31 | — | -US$4.16M | — |
| 2024-09-30 | — | -US$3.43M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.